EXEL News and Press, Exelixis Inc. From 10/19/22

Interest rates have been on the rise this year, and inflation still remains a big problem for the federal government. In September, the inflation rate was 8.2%, which is lower than it was in the previous month, but it's nowhere near the Fed's goal of 2%. What that tells investors is that mo...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET / 2:0...

JMP Securities has started Exelixis ( NASDAQ: EXEL ) with an outperform rating saying that company is cash flow-positive and Cabometyx (cabozantinib) is a strong franchise poised for growth. The firm has a $26 price target (~59% upside based on Monday's close). Analyst...

With the S&P 500 down more than 25% this year, t he stock market has not been a very attractive place for investors to be lately . However, now is the time when you can find exceptional stocks at a bargain -- an opportunity that will not be available in a bull market. ...

Summary I wanted to focus on an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns. I attempt to explain these precipitous bear market rallies, and how we anticipate them. I also talk about a tactical shift...

— Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor — Exelixis, Inc. (Nasdaq: EXEL) today announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers...

Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX) , Exelixis (NASDAQ: EXEL) , and Amgen (NASDAQ: AMGN) . Of course, the market downturn isn't over, and these three drugmakers could still...

Think of the biggest, richest corporations on the planet. They all started out much smaller but grew enormously over time. Investors who spotted their potential early on made fortunes. We asked three Motley Fool contributors to pick monster stocks in the making that just might make inve...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 21% over the past three months compared with a 6% gain for the S&P 500 . ...

Summary Performance has been poor over the past five years even as executive compensation remains on the high end. Cabozantinib continues to show promising sales growth and retention of market share in key indications such as renal cell carcinoma. Partnering efforts focus on n...